Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Barakat

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
Molecular Pharmacology|April 13, 2013
Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cellsLars Petter Jordheim, Khaled H Barakat, Laurence Heinrich-Balard, et al.
Frontiers in Oncology|April 4, 2022
Modulation of ERCC1-XPF Heterodimerization Inhibition <i>via</i> Structural Modification of Small Molecule Inhibitor Side-ChainsClaudia Weilbeer, David Jay, James C Donnelly, et al.
Journal of Microencapsulation|January 17, 2025
Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriersWalid Anwar, Abdulsalam M Kassem, Ayman Salama, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
Molecular Pharmacology|April 13, 2013
Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cellsLars Petter Jordheim, Khaled H Barakat, Laurence Heinrich-Balard, et al.
Frontiers in Oncology|April 4, 2022
Modulation of ERCC1-XPF Heterodimerization Inhibition <i>via</i> Structural Modification of Small Molecule Inhibitor Side-ChainsClaudia Weilbeer, David Jay, James C Donnelly, et al.
Journal of Microencapsulation|January 17, 2025
Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriersWalid Anwar, Abdulsalam M Kassem, Ayman Salama, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Pageof 12